Dose-finding and Pharmacokinetic Trial of Orally Administered D-24851 to Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2013
At a glance
- Drugs Indibulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ZIOPHARM Oncology
- 19 Jun 2009 Actual number of patients (47), lead investigator (Lewis J) added as reported by ClinicalTrials.gov.
- 19 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2007 Interim results were presented at the 2007 American Society of Clinical Oncology (ASCO) meeting.